A method for predicting whether a patient with cancer is likely to respond to a treatment is described. The method comprises measuring a value indicative of a level of certain biomarkers; calculating a total value using a weighted sum of the measured values; comparing the total value to a threshold value and when the total value is below the threshold value, determining that the patient is likely to respond to the treatment. Alternatively, the method comprises applying a model comprising coupled ordinary differential equations defining the rate of change of a plurality of biomarkers to predict a plurality of output values for the biomarkers for the treatment; selecting a biomarker; comparing the output value for the selected biomarker to an associated threshold value for the selected biomarker; and when the output value is below the associated threshold value, determining that the patient is likely to respond to the treatment.

The present invention relates to methods and compositions for the treatment of BAF-related disorders such as cancers and viral infections.

Provided are an anti-BCMA single-chain antibody scFv and a preparation method and application thereof. The preparation method is capable of artificially synthesizing a BCMA-targeted phage display library by combining site-directed mutagenesis and random mutagenesis technologies; and acquiring 3 new-type BCMA antigen-targeted scFv strains to serve as BCMA-targeted antibodies by combining a phage display technology.

Provided herein are methods of determining whether a subject will respond to a treatment for a neoplasia, neoplastic disorder, tumor, cancer or malignancy, the method comprising detecting the presence or amount of CDS 3 expressing cells in a biological sample from the subject, comparing the measured presence or amount to a reference presence or amount, wherein a modified measured presence or amount as compared to the reference presence or amount is indicative that the subject will or will not respond to the treatment for a neoplasia, neoplastic disorder, tumor, cancer or malignancy. Also described herein are methods of treating a neoplasia, neoplastic disorder, tumor, cancer or malignancy in a subject, the method comprising modulating CDS 3 activity or expression in a myeloid cell, or alternatively, comprising administering a population of CD33hi monocytes or CD33hi macrophages.

Provided is a method comprising determining polo-like kinase 1 (PLK1) activity in a cancer in a patient by measuring phosphorylation of a PLK1 target (a) prior to treatment of (i) the patient or (ii) a cancer sample from the patient with a PLK1 inhibitor, and (b) after the treatment.

Also provided is a method comprising determining polo-like kinase 1 (PLK1) activity in a cancer in a patient by measuring phosphorylation of a PLK1 target without treatment with a PLK1 inhibitor.

Provided herein are methods of detecting biomarkers and/or candidate biomarkers for glioblastoma and uses of the same.

The present invention describes methods of identifying drugs for the treatment or prevention of diabetes by measuring the activity of the human zinc transporter ZnT8 and pharmaceutical compositions.

Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Myelodysplastic syndrome (MDS) hematopoietic stem and progenitor cells (HSPC) translocate endosomal Toll-Like receptor (TLR)-9 to the plasma membrane, thereby sensitizing these clonal propagating cells to respective ligands in the microenvironment. TLR9 is the cognate receptor for RNA:DNA hybrids (R-loops) and unmethylated CpG oligonucleotides in oxidized mitochondrial DNA, the latter of which is abundant in the bone marrow microenvironment as a result of massive medullary pyroptotic cytolytic cell death. Both ligands are important danger-associated molecular patterns (DAMPs) triggering innate immune activation and chronic inflammation that contributes to MDS pathogenesis. In an effort to neutralize these DAMPs and disrupt this feed-forward inflammatory cascade, a chimeric protein was designed fusing the external epitopes of TLR9 to the Fc domain of human IgG4 to serve as a decoy receptor or ligand trap recognizing extracellular RNA:DNA hybrids (R-loops) and oxidized mitochondrial DNA.

Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.